At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,609 enrolled
Drug / intervention
Ad26.COV2.Sbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults
In Brief
A Phase 3 clinical trial evaluating Ad26.COV2.S for COVID-19 Prevention. Completed, enrolled 1,609 participants across 43 sites in 5 countries.
Detailed Summary
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Prevention
CountriesBrazil, Germany, Poland, South Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJun 2021
Primary CompletionJul 2023
TodayJul 2026
First PostedJun 1, 2021
Enrollment StartJun 18, 2021
Primary CompletionJul 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.1 years ago
Interventions
Ad26.COV2.Sbiological
Participants will receive intramuscular (IM) injections of Ad26.COV2.S.